HOME >> MEDICINE >> NEWS
The Lancet Oncology (TLO)

Billions of dollars are currently being spent on the search for effective drugs that will stop disease before it happens. Advances in genetic testing are providing more opportunities to find out which diseases people are likely to be at risk of developing--but this knowledge has put huge pressure on the medical profession to come up with ways of avoiding disease altogether. This month's leading edge questions the ethical issues involved in chemoprevention and highlights the difficulties in obtaining reliable data from chemoprevention clinical trials. It concludes: "Genetic tests have created a demand for chemoprevention that is threatening to push medicine to its limits; health services could be stretched beyond capacity because they are treating healthy people as well as the sick. To stop this snowball effect it is essential that one simple idea is kept in mind: you can spend all the money in the world on preventive medicine, but when people won't even stop smoking, can it really work?"

STOMACH CANCER - THE LATEST TARGET FOR THE 'MAGIC BULLET'

Gastrointestinal stromal tumours (GISTs) are the most recent cancer type to be targeted by the most effective new drug of recent years--imatinib mesylate. Effective treatment of GISTs has been hindered in the past by their characteristic resistance to conventional chemotherapy and persistent misclassification of these tumours in clinical studies has made pre-2000 data difficult to interpret. However, it is now known that most GISTs contain a mutation in the KIT tyrosine kinase, which means they are an ideal target for imatinib. In their review, Heikki Joensuu and colleagues discuss the recent advances in understanding of these difficult-to-treat tumours and discusses the impact of imatinib on outcome for patients with GISTs. The authors conclude that imatinib "has provided physicians with a well-tolerated and highly effective therapeutic option for a disease for which no systemic therapy existed previously".
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-424-4949
Lancet
30-Oct-2002


Page: 1 2

Related medicine news :

1. The Lancet calls for the creation of a world institute for risk evaluation
2. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
3. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
4. The Lancet Infectious Diseases (TLID)
5. The Lancet Neurology November press release
6. Lancet readers to join WHO election debate
7. The Lancet Oncology press release
8. The Lancet Neurology October press release
9. The Lancet neurology press release
10. The Lancet Neurology press release
11. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/9/2019)... ... 2019 , ... Pennsylvania College of Health Sciences, the area’s ... the fourth quarter of the 2018-2019 academic year, the school’s NCLEX scores continue ... College’s annual pass rate for the 2018-2019 academic year was 95.02%, maintaining the ...
(Date:11/7/2019)... ... ... Atlantic Ultraviolet Corporation makes it their business to fight the flu. The first ... season starts in October until March, Atlantic Ultraviolet makes it a point to host ... get their shot. , Ann Wysocki, COO of Atlantic Ultraviolet Corporation® says, “Atlantic Ultraviolet ...
(Date:11/7/2019)... SAN FRANCISCO (PRWEB) , ... November 07, 2019 , ... ... available in select southern markets. The product line includes a 4 and a 7 ... that [can] transmit diseases, such as Zika, West Nile Virus and Encephalitis, without exposing ...
(Date:11/7/2019)... ... November 07, 2019 , ... ... of Ignite and Expand got together on the Shamangelic Healing Podcast ... downloads skyrocketed. With a trending focus on learning ways to use bio-hacking to ...
(Date:11/6/2019)... Ky., and CENTENNIAL, Colo. (PRWEB) , ... November ... ... intelligence and consumer research platform, and the University of Kentucky Research Foundation (UKRF) ... of hemp-derived products. The agreement will give hemp-derived product companies access to the ...
Breaking Medicine News(10 mins):
(Date:11/5/2019)... MONTCLAIR, N.J. (PRWEB) , ... November 05, 2019 ... ... San Antonio, 555 South Alamo Street in Texas will be a timely program ... instruction in the management of chronic pain. , The Texas Medical Board requires ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... Nov. 13-14: How to Build a Sponsor Risk Management Program, Friday, Nov. ... Wednesday-Friday, Nov. 13-15, 2019 • Philadelphia, PA , https://www.fdanews.com/cwiche6gcp , ...
(Date:11/4/2019)... ... ... E-Z-C Pak Creator Dr. Sarath Malepati reeled in famed entrepreneur ... Shark Tank on ABC. EZC Pak is a physician formulated immune support pack composed ... use in colds and flu. , Dr. Malepati negotiated a $125,000 investment for a ...
Breaking Medicine Technology:
Cached News: